Physician profile
Robert Singer
NPI 1396716825
$2,802.69
in general payments reported to CMS, 2019-2025
24 companies · $1,017 in 2025
The $1,017 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $266 · 2021: $377 · 2022: $163 · 2023: $33.52 · 2024: $330 · 2025: $1,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,380.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $477.13 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $342.55 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $310.74 | 2019-2021 | |
| Medtronic, INC. | $283.88 | 2021-2025 | Symplicity G3, Corevalve Evolut R |
| Abbott Laboratories | $227.21 | 2019-2024 | Mitraclip, Xience Skypoint |
| Astrazeneca Pharmaceuticals Lp | $195.30 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.93 | 2019-2024 | Jardiance |
| Amgen INC. | $123.32 | 2019-2025 | Repatha, Repatha |
| Heartflow, INC. | $104.38 | 2025 | |
| Pfizer INC. | $73.76 | 2019-2025 | |
| Boston Scientific Corporation | $68.07 | 2019-2022 | |
| Edwards Lifesciences Corporation | $63.01 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Kestra Medical Technology Services, INC. | $56.02 | 2025 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $53.42 | 2019 | |
| Merck Sharp & Dohme LLC | $47.21 | 2024-2025 | Verquvo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $39.53 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.59 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $30.79 | 2025 | |
| Astellas Pharma US INC | $22.66 | 2019 | |
| Alnylam Pharmaceuticals INC. | $22.12 | 2025 | Onpattro |
| Regeneron Healthcare Solutions, INC. | $13.73 | 2019 | |
| Opko Pharmaceuticals, LLC | $13.52 | 2023 | Rayaldee |
| Akcea Therapeutics, INC. | $13.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Singer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.